INTERNATIONAL FLAVORS & FRAGRANCES INC.

Income statement: notes and sources

FY2022 income before taxes of -1625 is (derived) from disclosed operating loss, interest expense and other income; IFF describes it as $(1.6) billion.

Margin analysis (%): notes and sources

All margins (derived): Revenue CAGR. FY2021→FY2025 reported revenue CAGR is -1.7% (derived: 10,890 ÷ 11,656, four years). FY2022 (peak) → FY2025 is -4.3% per annum. Neither figure is economically meaningful without adjusting for divestitures: the businesses sold between 2022 and 2026 carried roughly $4.5 billion of annualised revenue at the point of disposal (Microbial Control, Savory Solutions, Cosmetic Ingredients, Pharma Solutions, Nitrocellulose, Flavors & Essences UK, René Laurent, SCL, and — pending — Food Ingredients at ≈$3.1 billion). On IFF's own comparable currency-neutral basis, sales grew 2% in FY2025 against a strong 6% prior-year comparable, and are guided to 2–4% growth in FY2026 on the continuing-operations base.

Balance sheet: notes and sources

FY2024 total debt and net debt are (derived) from short-term borrowings plus long-term debt, less cash, and exclude finance leases; FY2025 total debt of 5994 is as stated in the FY2025 10-K risk factors.

At 30 June 2026, total debt stood at $5,735 million, cash at $569 million and net debt at $5,166 million, with net debt / credit-adjusted EBITDA of 2.5× on a combined continuing-and-discontinued basis.

The deleveraging story is the balance sheet story. Net debt has fallen from $10.7 billion at the end of 2021 to $5.2 billion at mid-2026 — a 52% reduction — funded overwhelmingly by asset sales rather than by operating cash generation. Goodwill and intangibles have fallen from $26.9 billion to $11.9 billion (Q2 2026, continuing operations) over the same period, roughly half through impairment and half through disposal. Shareholders' equity has fallen from $21.1 billion to $14.0 billion. Even after all of this, goodwill and intangibles at $11.9 billion still represent 47% of total assets and 85% of book equity — the single largest remaining accounting risk on the balance sheet, and one that has produced impairments in four of the last five years.

Cash flow

FY2025 free cash flow of $256 million is the weakest of the period and deserves scrutiny. Operating cash flow fell $220 million year-on-year while capital expenditure rose $131 million to $594 million (5.5% of sales, versus management's earlier guidance of approximately 6% of sales for 2025). The operating cash decline is largely explained by the reversal of incentive-compensation accruals ($106 million outflow in 2025 versus a $190 million inflow in 2024 — a $296 million swing) and by cash regulatory and divestiture costs. This is a working-capital and one-off phasing problem rather than a deterioration in cash conversion, and H1 2026 confirms as much: operating cash flow of $679 million (up $311 million) and free cash flow of $378 million (up $284 million).

Ratio analysis: notes and sources

All ratios (derived) except net debt / credit-adjusted EBITDA, which is as reported by IFF. ROE and ROA use year-end balances. ROIC is likewise not calculable without a retrieved NOPAT and invested-capital series; note that on any reasonable construction, reported ROIC has been below cost of capital in four of the last five years given the impairment charges, while cash ROIC excluding purchase-accounting amortisation would be substantially higher.

Commentary on trends, inflections and drivers

FY2021 — the integration year. Revenue of $11.66 billion reflects eleven months of N&B. Reported profitability was severely depressed by $368 million of inventory step-up amortisation and $192 million of N&B transaction and integration costs. Adjusted operating EBITDA of $2.43 billion (20.8% margin) is the high-water mark of the entire period. Leverage exited the year at 4.1×.

FY2022 — the pricing year and the first impairment. Sales rose 6.3% to $12.44 billion on aggressive price recovery (comparable currency-neutral sales +9%), but the $2.25 billion Health & Biosciences goodwill impairment in Q3, plus a $120 million long-lived asset impairment, produced a $(7.21) reported loss per share. Adjusted EBITDA margin compressed 110 basis points to 19.7% as pricing lagged input cost inflation.

FY2023 — the trough. The inflection. Sales fell 7.7% to $11.48 billion; adjusted EBITDA fell 19% to $1.98 billion and margin collapsed 250 basis points to 17.2%. The driver was a deliberate destocking programme: management reduced inventory, and the resulting unfavourable manufacturing absorption compounded a genuine volume decline as customers ran down their own inventories. A further $2.62 billion goodwill impairment produced $(10.05) of reported loss per share. Cash generation remained strong ($936 million free cash flow) — evidence that the problem was accounting and absorption, not cash economics.

FY2024 — stabilisation under new management. Revenue flat at $11.48 billion but gross margin recovered 380 basis points to 35.9% as destocking annualised out and pricing held. Adjusted EBITDA rebounded 11% to $2.20 billion. The dividend was cut roughly 50%, saving over $300 million of annual cash, and interest expense fell $75 million on lower debt. Reported EPS returned to positive at $1.04. Assets held for sale ballooned to $3.06 billion — the Pharma Solutions perimeter.

FY2025 — portfolio surgery. Reported revenue fell 5% to $10.89 billion entirely on divestiture; comparable currency-neutral sales rose 2% and comparable EBITDA rose 7%. Gross margin reached a period high of 36.2%. Three items dominate the reported result: the $1.153 billion segment-reorganisation goodwill impairment, the $488 million gain on debt extinguishment from the tender offers, and $115 million of held-for-sale losses. Net of these, the underlying business performed to plan. Interest expense fell a further 25% to $229 million. Leverage reached 2.6×.

H1 2026 — the clean base emerges. On continuing operations, sales of $3.86 billion, adjusted operating EBITDA of $841 million and a 21.8% margin. Comparable currency-neutral sales +4%, EBITDA +8%. Free cash flow up $284 million year-on-year. This is, for the first time since 2021, a set of numbers that describes the business management intends to run.

Management guidance summary

Beyond FY2026 IFF has not published medium-term financial targets. The only forward commitments are the leverage corridor, the buyback completion date of end-2027, and the stranded-cost elimination schedule (two-thirds within one year of close, substantially all within two).

Consensus expectations

Sell-side consensus, as summarised by aggregators, places the average twelve-month target between $87.85 and $95.24, with a central tendency around $91–93 against a $84.23 spot price — implying roughly 8–11% upside. Rating distribution is approximately 15–16 buy, 4 hold, 0 sell across the 17–20 analysts covering. Forward revenue expectations remain negative on a reported basis (one aggregator cites an expected 2.7% revenue decline over the next twelve months) because the reporting perimeter continues to shrink; this is a mechanical rather than a fundamental expectation.

Bull case

1. The pro-forma balance sheet is dramatically better than the market has yet marked. Applying $3.8 billion of CVC proceeds against $5.17 billion of net debt leaves roughly $1.4 billion of net debt against $1.53–1.60 billion of continuing EBITDA — under 1.0× turns, before any buyback. That is investment-grade-comfortable with room to spare, creates the conditions for a rating upgrade from the lowest investment-grade notch, and lowers cash interest from the $229 million paid in FY2025. Interest expense has already fallen 40% from the FY2023 peak.

2. The retained portfolio is structurally better than the one being sold, and the numbers already prove it. Continuing-operations adjusted EBITDA margin was 20.9% in Q2 2026 versus 19.7% including discontinued operations, and 21.8% for the first half. Health & Biosciences alone runs at 24.7–25.0%. Comparable currency-neutral EBITDA growth of 8% in H1 2026 on 4% sales growth demonstrates operating leverage that the consolidated 2021–2024 numbers never showed. Add approximately $100 million of stranded-cost elimination — worth roughly 6% of continuing EBITDA — and the FY2028 earnings base looks materially different from anything in the historical series.

3. Capital return is large, funded and committed. A $2.5 billion authorisation against a $21.5 billion market capitalisation is 11.6% of the company, with $500 million already scheduled for H2 2026 via accelerated repurchase and completion targeted by end-2027. Management is buying at approximately 20× adjusted EPS ex amortisation with the balance sheet fixed — a materially better use of capital than the acquisitions of 2018 and 2021.

Bear case

1. The adjusted-versus-reported gap is not closing, and the adjustments are recurring. FY2025 adjusted EPS ex amortisation of $4.20 sits against reported EPS of $(1.46) — a $5.66 gap. The components are not one-offs in any economically meaningful sense: $568 million of purchase-accounting amortisation recurs annually and will for years; goodwill impairment has appeared in four consecutive years; regulatory costs rose to $81 million in H1 2026 from $64 million; divestiture and strategic-initiative costs have been continuous since 2021. An investor paying 20× a number that excludes 27% of EBITDA in amortisation and a decade of impairments is making a strong assumption about where economic earnings actually sit.

2. Cash conversion is weak and capex is rising into a smaller business. FY2025 free cash flow of $256 million represents 12% conversion of adjusted EBITDA and 2.4% of sales. Capex rose to $594 million — 5.5% of sales, and the highest of the five-year period — even as revenue shrank. H1 2026 was better, but the CVC transaction removes approximately $520 million of EBITDA while the capital intensity of the retained fermentation and naturals businesses is, if anything, higher than that of Food Ingredients. Management has published no free cash flow target.

3. The unresolved antitrust exposure is asymmetric and unquantified. DOJ closure is genuinely good news, but the European Commission, UK CMA, Swiss COMCO and Mexican COFECE investigations remain open, Canadian class actions are pending, and IFF has applied for leniency in a number of jurisdictions — which is what a company does when it believes it has exposure. The EC has already fined IFF €15.9 million for destroying evidence during an inspection, which will not help in the substantive case. EU cartel fines are assessed against relevant turnover and can reach 10% of global revenue. IFF has taken $43.25 million of provision and settled two US civil tiers for $37 million combined; the European tail is not provided for in any disclosed amount.

Catalysts and monitorables, next twelve months

Concluding analyst verdict

IFF in September 2026 is a company that has finished admitting its mistake and has not yet been credited for fixing it. The N&B merger, at approximately $26 billion, produced $6.09 billion of goodwill impairments in four years, three reported net losses in five, and a share price that halved. Erik Fyrwald's answer since February 2024 has been unusually unsentimental: sell Pharma Solutions, sell Nitrocellulose, sell Cosmetic Ingredients, sell Soy Crush, sell Food Ingredients, cut the dividend, tender the debt, rebuild the board. Net debt is down 52% from the 2021 peak. Guidance has been met two years running. Continuing-operations margin is 20.9% and rising, R&D intensity has gone from 4.8% to over 8%, and $2.5 billion of buyback capacity is authorised against a $21.5 billion market capitalisation.

The counter-argument is equally clear. Free cash flow of $256 million in FY2025 was the worst of the period, and the adjusted earnings on which the stock is valued exclude $568 million of annual amortisation that will not disappear for years. Regulatory costs are rising, not falling, and the European antitrust proceedings — where IFF has sought leniency and has already been fined for obstruction — represent a liability nobody can size. The CVC close is still nine months away and the second $2.0 billion buyback tranche depends on it.

On balance, the risk-reward has improved materially, and the market's roughly 42% rally off the October 2025 low reflects that. At approximately 14.6× pro-forma continuing-operations EBITDA, IFF is no longer obviously cheap, but the deleveraging is real, the retained assets are the good ones, and the credit ratings sit one notch above high yield with clear upgrade logic. The single largest determinant of the next two years is not operational: it is whether Brussels, London, Bern and Mexico City follow Washington in closing their files.

---

End of dossier. Prepared 12 September 2026 from publicly available sources. Figures marked "(derived)" are calculations performed on disclosed inputs. Where IFF's own disclosures conflict — notably the September 2024 versus September 2025 dating of the Flavors & Essences UK divestiture, and the 150-facilities-in-40-countries versus 170-facilities-in-30-countries footprint statements — both versions have been reported and the conflict flagged rather than resolved. This document is not investment advice.